3rd phase of the clinical trial of the Covid-19 vaccine ‘covishield’ has begun from 21st September 2020, at the state-run Sassoon General Hospital in Pune, Maharashtra. The vaccine is being developed by Oxford University and manufactured by the Serum Institute of India (SII).
Dr. Muralidhar Tambe, Dean of Sassoon General Hospital reported, “We have started the phase-III trials of the vaccine candidate. We will administer a dose of 150 to 200 volunteers.”
Also, they shared that all Those who are willing to volunteer for vaccination can contact on the following numbers–8550960196, 8104201267. The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, being developed by the University of Oxford.
Covaxin human clinical trials to begin at AIIMS Delhi
People are eagerly waiting for the COVID-19 vaccine, so as to get back to their normal schedules. Covid-19 has affected the lives of so many people in different ways and now vaccines can only make some difference. Earlier so many institutions tried developing vaccines but none of them made it right successfully and each of them had some of the limitations. People have high hopes from this upcoming Covishield, to work.
2nd trial of Covishield was done at Bharti Vidyapeeth Medical College and King Edward Memorial (KEM) Hospital in Pune. Earlier the Drugs Controller General of India (DCGI) directed the SII to hold on phase – 2 and 3 clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of ‘an unexplained illness’ in a participant in the study. Poonam Pandey files an FIR against her husband
After the 3 says of order DCGI allowed the Serum Institute to restart the trial of the Covishield vaccine, when the pharma major submitted the recommendations of the DSMB. Then they requested permission to restart the registration in the subject clinical trial of the vaccine.
Another COVID-19 vaccine is also developed by Novavax, whose trial will start from the next month in Serum Institute. US drug developer Novavax Inc earlier announced that it has revised its deal with world’s largest vaccine manufacturing company Serum Institute of India (SII) in order to produce 2 billion doses of Covid-19 vaccines.